References
- Anturan Reinfarction Italian Study Group. Sulphinpyrazone in post-myocardial infarction. Lancet 1982; i: 237–242
- Anturane Reinfarction Trial Research Group. Sulphinpyrazone in the prevention of sudden death after myocardial infarction. New England Journal of Medicine 1978; 298: 289–295
- Anturane Reinfarction Trial Research Group. Sulphinpyrazone in the prevention of sudden death after myocardial infarction. New England Journal of Medicine 1980; 302: 250–256
- Arabi Y., Dimock F., Burdon D. W., Alexander-Williams J., Keighley M. R. B. Influence of metronidazole and neomycin on colonic microflora in healthy volunteers. Gut 1977; 18: A969
- Berghouse L., Hori S., Hill M., Hudson M., Lennard-Jones J., Rogers E. Comparison between the bacterial and oligosaccharide content of ileostomy effluent in subjects taking diets rich in refined or unrefined carbohydrate. Gut 1984; 25: 1071–1077
- Borriello S. P., Hudson M. J., Hlll M. J. Investigation of the gastrointestinal bacterial flora. Clinical Gastroenterology 1978; 7: 329–349
- Brogden R. N., Heel R. C., Speight T. M., Avery G. S. Sulindac: a review of its pharmacological properties and therapeutic efficiency in rheumatic diseases. Drugs 1978; 16: 97–114
- Davis P. J., Guenthner L. E. Sulindac oxidation reduction by microbial cultures; microbial models of mammalian metabolism. Xenobiotica 1985; 15: 845–857
- Del Maschio A., Livio M., Cerletti C., Degaetano G. Inhibition of human platelet cyclo-oxygenase activity by sulfinpyrazone and three of its metabolites. European Journal of Pharmacology 1984; 101: 209–214
- Drasar B. S., Hill M. J. Human Intestinal Flora. Academic Press, London 1974; 3–8
- Duggan D. E., Hooke K. F., Risley E. A., Shan T. Y., Van Arman C. G. Identification of the biologically active form of sulindac. Journal of Pharmacology and Experimental Therapeutics 1977; 201: 8–12
- Duggan D. E., Hooke K. F., Noll R. M., Hucker H. B., Van Arman C. G. Comparative disposition of sulindac and metabolites in five species. Biochemical Pharmacology 1978; 27: 2311–2320
- Hudson M. J., Hill M. J., Elliott P. R., Berghouse L. M., Burnham W. R., Lennard-Jones J. E. The microbial flora of the rectal mucosa and faeces of patients with Crohn's disease before and during antimicrobial chemotherapy. Journal of Medical Microbiology 1984; 18: 335–345
- Kucers A., Bennett N. The Use of Antibiotics. William Heineman Medical Books, London 1979
- Pay G. F., Wallis R. B., Zelaschi D. A metabolite of sulphinpyrazone that is largely responsible for the effect of the drug on the platelet prostaglandin pathway. Biochemical Society Transactions 1980; 8: 727–728
- Ratnayake J. H., Hanna P. E., Anders M. W., Duggan D. E. In vitro reduction of sulindac by rat hepatic cytosolic enzymes. Drug Metabolism and Disposition 1981; 9: 85–87
- Renwick A. G., Evans S. P., Sweatman T. W., Cumberland J., George C. F. The role of the gut flora in the reduction of sulphinpyrazone in the rat. Biochemical Pharmacology 1982; 31: 2649–2656
- Smith M. H. Do intestinal parasites require oxygen. Nature 1969; 223: 1129–1132
- Strong H. A., Renwick A. G., George C. F. The site of reduction of sulphinpyrazone in the rabbit. Xenobiotica 1984a; 14: 815–826
- Strong H. A., Oates J., Sembi J., Renwick A. G., George C. F. Role of the gut flora in the reduction of sulfinpyrazone in humans. Journal of Pharmacology and Experimental Therapeutics 1984b; 230: 726–732
- Strong H. A., Warner N. J., Renwick A. G., George C. F. Sulindac metabolism: the importance of an intact colon. Clinical Pharmacology and Therapeutics 1985; 38: 387–393
- Strong H. A., Angus R., Oates J., Sembi J., Howarth P., Renwick A. G., George C. F. The effects of ischaemic heart disease, Crohn's disease and anti-microbial therapy on the pharmacokmetics of sulphinpyrazone. Clinical Pharmacokinetics 1986; 11: 402–410
- Tatsumi K., Kitamura S., Yamada S. Sulfoxide reductase activity of liver aldehyde oxidase. Biochimica et Biophysica Acta 1983; 747: 86–92
- Yeung T. C., Sudlow G., Koch R. L., Goldman P. Reduction of nitroheterocyclic compounds by mammalian tissues. in vivo. Biochemical Pharmacology 1983; 32: 2249–2253